Related Experiment Videos
[Neoadjuvant hormonal therapy for prostate cancer].
1Department of Urology, Kyoto Prefectural University of Medicine, 465 Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 2, 2001
Summary
Neoadjuvant hormonal therapy before radical prostatectomy significantly reduced positive surgical margins in T2 prostate cancer. However, it did not improve survival outcomes or reduce metastasis, warranting further investigation.
Area of Science:
- Urology
- Oncology
- Surgical Oncology
Context:
- Radical prostatectomy is a primary treatment for localized prostate cancer.
- Neoadjuvant hormonal therapy (NHT) is explored to improve surgical outcomes.
- Previous studies suggested potential benefits of NHT in reducing positive surgical margins.
Purpose:
- To evaluate the efficacy of neoadjuvant hormonal therapy (NHT) in improving outcomes after radical prostatectomy for clinically localized prostate cancer.
- To assess the impact of NHT on surgical margins, metastasis, and patient survival.
Summary:
- A review of seven randomized trials indicated that NHT significantly decreased positive surgical margins in clinical T2 prostate cancer patients undergoing prostatectomy.
- However, NHT did not alter seminal vesicle invasion or lymph node metastasis rates.
- No significant differences were observed in operative complications, blood loss, or hospital stay.
- Crucially, NHT did not improve prostate-specific antigen-free survival rates within a 4-year follow-up period.
Impact:
- Current evidence does not support the routine use of neoadjuvant hormonal therapy before radical prostatectomy for localized prostate cancer.
- The findings suggest NHT remains investigational, with further research needed to determine optimal duration and survival benefits.
- This review highlights the need for outcome-based evidence to guide clinical practice regarding neoadjuvant hormonal therapy.